| [1] |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
doi: 10.1097/CM9.0000000000001474
|
| [2] |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.000000000-0002108.
doi: 10.1097/CM9.000000000-0002108
|
| [3] |
Saklani A, Pandey D, Patel S. RAPIDO protocol: a promising approach for high-risk locally advanced rectal cancers[J]. Lancet Oncol, 2021, 22(1): 2-3. DOI: 10.1016/S1470-2045(20)30643-4.
doi: 10.1016/S1470-2045(20)30643-4
|
| [4] |
Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radio-therapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(1): 29-42. DOI: 10.1016/S1470-2045(20)30555-6.
doi: 10.1016/S1470-2045(20)30555-6
pmid: 33301740
|
| [5] |
Tanaka T, Terai Y, Fujiwara S, et al. Neoadjuvant intra-arterial chemotherapy using an original four-lumen double-balloon catheter for locally advanced uterine cervical cancer[J]. Oncotarget, 2018, 9(102): 37766-37776. DOI: 10.18632/oncotarget.26518.
doi: 10.18632/oncotarget.26518
|
| [6] |
Liu X, Lin H, Wang Q, et al. Drug-eluting beads bronchial arterial chemoembolization plus intercostals arterial infusion chemotherapy is effective and well-tolerated in treating non-small cell lung cancer patients with refractory malignant pleural effusion[J]. J Thorac Dis, 2021, 13(4): 2339-2350. DOI: 10.21037/jtd-20-1603.
doi: 10.21037/jtd-20-1603
|
| [7] |
Qiu B, Zhang X, Tsauo J, et al. Transcatheter arterial infusion for pancreatic cancer: a 10-year National Cancer Center experience in 115 patients and literature review[J]. Abdom Radiol (NY), 2019, 44(8): 2801-2808. DOI: 10.1007/s00261-019-02022-2.
doi: 10.1007/s00261-019-02022-2
|
| [8] |
Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 293-313. DOI: 10.1038/s41575-020-00395-0.
doi: 10.1038/s41575-020-00395-0
pmid: 33510460
|
| [9] |
张景岚. 结直肠癌肝转移瘤局部介入治疗应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 79-82. DOI: 10.11904/j.issn.1002-3070.2020.01.015.
doi: 10.11904/j.issn.1002-3070.2020.01.015
|
| [10] |
Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses[J]. J Clin Oncol, 2011, 29(28): 3768-3774. DOI: 10.1200/JCO.2011.36.4539.
doi: 10.1200/JCO.2011.36.4539
pmid: 21859995
|
| [11] |
De Felice F, Benevento I, Magnante AL, et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: oxaliplatin in neoadjuvant treatment for rectal cancer[J]. BMC Cancer, 2017, 17(1): 325. DOI: 10.1186/s12885-017-3323-4.
doi: 10.1186/s12885-017-3323-4
|
